» Articles » PMID: 20190302

Bone-marrow-derived Mononuclear Cells with a Porous Hydroxyapatite Scaffold for the Treatment of Osteonecrosis of the Femoral Head: a Preliminary Study

Overview
Date 2010 Mar 2
PMID 20190302
Citations 36
Authors
Affiliations
Soon will be listed here.
Abstract

We have investigated the effectiveness of the transplantation of bone-marrow-derived mononuclear cells (BMMNCs) with interconnected porous calcium hydroxyapatite (IP-CHA) on early bone repair for osteonecrosis of the femoral head. We studied 22 patients (30 hips) who had osteonecrosis with a minimum follow-up of one year after implantation of BMMNCs. The mean age at surgery was 41 years (18 to 64) and the mean period of follow-up was 29 months (19 to 48). In a control group, cell-free IP-CHA was implanted into a further eight patients (9 hips) with osteonecrosis of the femoral head and the outcomes were compared. A reduction in the size of the osteonecrotic lesion was observed subsequent to hypertrophy of the bone in the transition zone in the BMMNC group. In three patients in the treatment group progression to extensive collapse was detected. In the control group subtle bone hypertrophy was observed, but severe collapse of the femoral head occurred in six of eight hips. In this limited study the implantation of BMMNCs and IP-CHA appears to confer benefit in the repair of osteonecrosis and in the prevention of collapse.

Citing Articles

Orthobiologic therapies delay the need for hip arthroplasty in patients with avascular necrosis of the femoral head: A systematic review and survival analysis.

Zaffagnini M, Boffa A, Andriolo L, Raggi F, Zaffagnini S, Filardo G Knee Surg Sports Traumatol Arthrosc. 2024; 33(3):1112-1127.

PMID: 39543728 PMC: 11848991. DOI: 10.1002/ksa.12532.


Autologous concentrated bone marrow injection for precollapse osteonecrosis of the femoral head concurrent with contralateral total hip arthroplasty: protocol for a clinical trial.

Homma Y, Yamasaki T, Tashiro K, Okada Y, Shirogane Y, Watari T BMJ Open. 2024; 14(5):e082243.

PMID: 38719293 PMC: 11086415. DOI: 10.1136/bmjopen-2023-082243.


Stem cell therapy combined with core decompression versus core decompression alone in the treatment of avascular necrosis of the femoral head: a systematic review and meta-analysis.

Li M, Chen D, Ma Y, Zheng M, Zheng Q J Orthop Surg Res. 2023; 18(1):560.

PMID: 37533122 PMC: 10398910. DOI: 10.1186/s13018-023-04025-8.


Bone tissue engineering for treating osteonecrosis of the femoral head.

Bian Y, Hu T, Lv Z, Xu Y, Wang Y, Wang H Exploration (Beijing). 2023; 3(2):20210105.

PMID: 37324030 PMC: 10190954. DOI: 10.1002/EXP.20210105.


Grafting of autologous concentrated bone marrow processed using a point-of-care device for patients with osteonecrosis of the femoral head: A phase 1 feasibility and safety study.

Homma Y, Masubuchi Y, Shirogane Y, Amano H, Muramoto Y, Nagao M Regen Ther. 2022; 20:18-25.

PMID: 35350421 PMC: 8933728. DOI: 10.1016/j.reth.2022.03.002.